Zevra Therapeutics, Inc. (ZVRA)
8.80
-0.09
(-1.01%)
USD |
NASDAQ |
Feb 20, 16:00
8.81
+0.01
(+0.11%)
After-Hours: 20:00
Zevra Therapeutics SG&A Expense (Quarterly) : 16.94M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Verastem, Inc. | 21.01M |
| ADMA Biologics, Inc. | 23.05M |
| ACADIA Pharmaceuticals, Inc. | 133.40M |
| Alnylam Pharmaceuticals, Inc. | 325.37M |
| Savara, Inc. | 9.627M |